These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30789540)

  • 1. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
    Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL
    Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
    Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
    Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach.
    Lund JL; Webster-Clark MA; Hinton SP; Shmuel S; Stürmer T; Sanoff HK
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1579-1587. PubMed ID: 33015888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
    Boyle JM; Kuryba A; Cowling TE; van der Meulen J; Fearnhead NS; Walker K; Braun MS; Aggarwal A
    Int J Cancer; 2022 Jan; 150(2):335-346. PubMed ID: 34520572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construct validity of medicare chemotherapy claims: the case of 5FU.
    Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
    Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.
    Zheng Z; Hanna N; Onukwugha E; Reese ES; Seal B; Mullins CD
    Cancer Med; 2014 Feb; 3(1):124-33. PubMed ID: 24403130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age and adjuvant chemotherapy use after surgery for stage III colon cancer.
    Schrag D; Cramer LD; Bach PB; Begg CB
    J Natl Cancer Inst; 2001 Jun; 93(11):850-7. PubMed ID: 11390534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.
    Green SL; Dawe DE; Nugent Z; Cheung WY; Czaykowski PM
    J Geriatr Oncol; 2019 Jan; 10(1):132-137. PubMed ID: 30104156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.
    O'Connor ES; Greenblatt DY; LoConte NK; Gangnon RE; Liou JI; Heise CP; Smith MA
    J Clin Oncol; 2011 Sep; 29(25):3381-8. PubMed ID: 21788561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
    Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
    Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.